share_log

Avalo Therapeutics | 8-K/A: Current report (Amendment)

Avalo Therapeutics | 8-K/A: Current report (Amendment)

Avalo Therapeutics | 8-K/A：重大事件(修正)
美股sec公告 ·  06/24 16:06
Moomoo AI 已提取核心訊息
Avalo Therapeutics, Inc. has filed an amendment to its Form 8-K, originally submitted on March 28, 2024, to include restated financial statements for AlmataBio, Inc. for the year ending December 31, 2023. The amendment, filed on June 24, 2024, addresses a misstatement in AlmataBio's operating expenses. Avalo had completed the acquisition of AlmataBio on March 27, 2024, and the restated financials reflect adjustments to research and development expenses and general and administrative expenses. The restatement increased AlmataBio's net loss by $153,000 for the year. Avalo's acquisition of AlmataBio was a stock-for-stock transaction, with AlmataBio's equity exchanged for Avalo common stock and non-voting convertible preferred stock. The transaction also included a $7.5 million cash payment to AlmataBio stockholders and potential future milestone payments.
Avalo Therapeutics, Inc. has filed an amendment to its Form 8-K, originally submitted on March 28, 2024, to include restated financial statements for AlmataBio, Inc. for the year ending December 31, 2023. The amendment, filed on June 24, 2024, addresses a misstatement in AlmataBio's operating expenses. Avalo had completed the acquisition of AlmataBio on March 27, 2024, and the restated financials reflect adjustments to research and development expenses and general and administrative expenses. The restatement increased AlmataBio's net loss by $153,000 for the year. Avalo's acquisition of AlmataBio was a stock-for-stock transaction, with AlmataBio's equity exchanged for Avalo common stock and non-voting convertible preferred stock. The transaction also included a $7.5 million cash payment to AlmataBio stockholders and potential future milestone payments.
Avalo Therapeutics公司已經對原先於2024年3月28日提交的8-K表格進行修改，以包括AlmataBio公司截至2023年12月31日的重述財務報表。這項修正在2024年6月24日提交，在解決AlmataBio營業費用的錯誤方面發揮了作用。 Avalo於2024年3月27日完成對AlmataBio的收購，重述的財務報表反映了對研發費用和管理費用的調整。公司重述財務報表後，AlmataBio的淨虧損增加了$153,000 。Avalo對AlmataBio的收購是一項股票交換交易，其中AlmataBio的股權被交換爲Avalo的普通股和非投票可轉換優先股。交易還包括向AlmataBio股東支付750萬美元的現金，並可能在未來支付里程碑費用。
Avalo Therapeutics公司已經對原先於2024年3月28日提交的8-K表格進行修改，以包括AlmataBio公司截至2023年12月31日的重述財務報表。這項修正在2024年6月24日提交，在解決AlmataBio營業費用的錯誤方面發揮了作用。 Avalo於2024年3月27日完成對AlmataBio的收購，重述的財務報表反映了對研發費用和管理費用的調整。公司重述財務報表後，AlmataBio的淨虧損增加了$153,000 。Avalo對AlmataBio的收購是一項股票交換交易，其中AlmataBio的股權被交換爲Avalo的普通股和非投票可轉換優先股。交易還包括向AlmataBio股東支付750萬美元的現金，並可能在未來支付里程碑費用。
有用
沒用

該公告為獨立文件：

獨立文件1

獨立文件2

獨立文件3

獨立文件4

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息